Aurora kinase inhibitors: which role in the treatment of chronic myelogenous leukemia patients resistant to imatinib?

  • Giovanni Martinelli | giovanni.martinelli2@unibo.it Institute of Hematology and Medical Oncology "L. e A. Seràgnoli", Bologna, Italy, Italy.
  • Simona Soverini Department of Hematology/Oncology “L. and A. Seràgnoli”, University of Bologna, Italy.
  • Ilaria Iacobucci Department of Hematology/Oncology “L. and A. Seràgnoli”, University of Bologna, Italy.
  • Cristina Papayannidis Department of Hematology/Oncology “L. and A. Seràgnoli”, University of Bologna, Italy.
  • Daniela Cilloni Division of Hematology and Internal Medicine, Department of Clinical and Biological Science, University of Turin, Italy.
  • Michele Baccarani Department of Hematology/Oncology “L. and A. Seràgnoli”, University of Bologna, Italy.

Abstract

At present, there are no compounds in clinical development in the field of chronic myeloid leukemia (CML) or Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL) that have been documented to harbor significant activity against the imatinib-resistant T315I mutation. Recent reports on the pre-clinical activity of some emerging tyrosine kinase inhibitors such as ON012380, VX-680 and PHA-739358 promise possible clinical efficacy against this specific Bcr-Abl mutant form. Here, we focus on the role of aurora kinase inhibitor VX-680 and PHA-739358 in blocking the leukemogenic pathways driven by wild-type and T315I-Bcr-Abl in CML or Ph+ ALL by reviewing recent research evidence. We also discuss the possibility of employing aurora kinase inhibitors as a promising new therapeutic approach in the treatment of CML and Ph+ ALL patients resistant to first and second generation TK inhibitors.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.
openaccess logo
Published
2009-02-18
Info
Issue
Section
Reviews
Keywords:
Aurora kinase inhibitors, Chronic Myelogenous Leukemia
Statistics
  • Abstract views: 2892

  • PDF: 468
  • HTML: 6379
How to Cite
Martinelli, G., Soverini, S., Iacobucci, I., Papayannidis, C., Cilloni, D., & Baccarani, M. (2009). Aurora kinase inhibitors: which role in the treatment of chronic myelogenous leukemia patients resistant to imatinib?. Hematology Reports, 1(1), e1. https://doi.org/10.4081/hr.2009.e1